Lodo Therapeutics Corp. (Lodo), a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously undruggable disease targets, today announced that it has completed the acquisition of Hibiskus BioPharma, Inc. (Hibiskus).
